• Media, News & Publications

    For interviews and media information please contact us here.


    Press Releases:
    January 31, 2017:SignalRx Pharmaceuticals Announces Breakthrough Results on Novel Anti-Cancer Dual PI3K-BRD4 Inhibition Paradigm in PNAS Publication Read Here

    November 7th, 2016: SignalRx Announces Publication of Research Results on SF1126 as a First-In-Class Dual PI3K/BRD4 Inhibitor for Treating HCC Read Here

    April 19th, 2016: SignalRx Presents at AACR Annual Meeting on First-In-Class Dual PI3K/BRD4 Inhibitors for Treating Cancer Read Here

    August 19th, 2015: SignalRx Pharmaceuticals Inc. Announces First Pediatric Cancer Patient Treated with the PI-3 Kinase Inhibitor SF1126 Read Here

    August 11th, 2015: Novel Therapeutic Agent for Pediatric Cancer Developed at UC San Diego in Clinical Trials – Phase I trial to launch at 14 hospitals nationally, first-time used in children Read Here

    May 18th, 2015: SignalRx Pharmaceuticals Inc. Awarded STTR Grant from the National Institutes of Health for Development of Dual PI3 Kinase/Bromodomain Inhibitors as Anticancer Agents Read Here

    April 21, 2015: SignalRx Presents at 10th Annual Drug Discovery Chemistry Conference on its Dual Kinase-Epigenetic Inhibitors for Treating Cancer Read Here

    September 15th, 2014: SignalRx Presents at AACR Conference on its Dual Kinase-Epigenetic Inhibitors for Treating Cancer

    November 12th, 2013: SignalRX Pharmaceuticals Issued U.S.Patent Covering Novel Kinase Inhibitors For Treating Cancer and Other Diseases

    Recent company-related publications:

    De P, Dey N, Terakedis B, Bergsagel PL, Li ZH, Mahadevan D, Garlich JR, Trudel S, Makale MT, Durden DL:  “An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.”  Cancer Chemother Pharmacol 2013, Vol. 71, Issue 4, pp 867-881. doi: 10.1007/s00280-013-2078-0

    Morales GA, Garlich JR, Su J, Peng X, Newblom J, Weber K, Durden DL:  “Synthesis and Cancer Stem Cell-Based Activity of Substituted 5-Morpholino-7H-thieno[3,2-b]pyran-7-ones Designed as Next Generation PI3K Inhibitors.”  J Med Chem 2013, Vol. 56, Issue 5, pp 1922-1939. doi: 10.1021/jm301522m

    Qi W, Stejskal A, Morales C, Cooke LS, Garlich JR, Mahadevan D:  “SF1126, a Pan-PI3K Inhibitor has Potent Pre-Clinical Activity in Aggressive B-Cell Non-Hodgkin Lymphomas by Inducing Cell Cycle Arrest and Apoptosis.” J Cancer Sci Ther 2012, Vol. 4, Issue 7, pp 207-213. doi: 10.4172/1948-5956.1000143

    Mahadevan D, Chiorean EG,  Harris WB, Von Hoff DD, Stejskal-Barnett A, Qi W , Anthony SP, Younger AE, Rensvold DM, Cordova F, Shelton CF, Becker MD, Garlich JR, Ramanathan RK:  “Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.” Eur J Cancer 2012, Vol. 48, Issue 18, pp 3319-3327. doi: 10.1016/j.ejca.2012.06.027

    Garlich JR, De P, Dey N, Su J, Peng X, Miller A, Murali R, Lu Y, Mills GB, Kundra V, Shu H, Peng Q, Durden DL:  “A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.” Cancer Res 2008, Vol. 68, Issue 1, pp 206-215. doi: 10.1158/0008-5472.CAN-07-0669